S Sridhar et al. Inflamm Bowel Dis 2018; 24: 2086-92. This retrospective pediatric study with 409 patients examined dermatologic manifestations on anti-TNF therapy. 47 (11.4%) had dermatologic findings recorded including 33 with psoriasis, 28 with infections, and 10 with eczema (some had multiple skin findings). The majority were able to continue with current anti-TNF regmimen, including 60% of those with psoriasis.
Related blog posts:
- Pattern of Skin Reactions to Anti-TNF Agents | gutsandgrowth
- Immune-Mediated Reactions to Anti-TNFs and What to Do About Them | gutsandgrowth
- Characteristics of Skin Lesions Associated with Anti-Tumor Necrosis Factor Therapy | gutsandgrowth
- IBD Shorts -Skin, Adalimumab Kinetics | gutsandgrowth
NA Rozette et al. Inflamm Bowel Dis 2018; 24: 2007-14. This study with 50 subjects showed good safety of rapid versus standard infliximab infusions. One interesting aspect of their study which included a retrospective arm (standard infusion) and a prospective arm (rapid infusion) was a declining use of premedication, though even in their prospective group 60% received premedication including the combination of acetaminophen, benadryl, and methylprednisolone in 30%. There were two patients in the rapid infusion with mild reactions who reverted to standard infusion rates.
CJ Moran, JL Kaplan, HS Winter. Inflamm Bowel Dis 2018; 24: 2048-52. This study with 199 subjects with active Crohn’s disease (CD) (21-86 years) –had their BioBank blood tested for 5 common CRP genetic variants. Some specific variants, rs2794520TT & rs1800947, were associated with lower CRP levels. This study helps explain why CRP is not a useful marker in some patients with CD.
Sunshine Meadows, Banff
